Page 57 - Read Online

Page 18 of 23 Koukourakis et al. J Cancer Metastasis Treat 2022;8:38 https://dx.doi.org/10.20517/2394-4722.2022.43

DECLARATIONS
Authors’ contributions
Performed search of literature, analysis of data, writing of the first draft of the study and final approval of
the manuscript: Koukourakis IM, Desse D, Papadimitriou M
Made substantial contributions to conception and design of the study, interpretation, writing of the study
and final approval of the manuscript: Papadimitriou C, Konstadoulakis M, Zygogianni A

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021;71:7-33. DOI PubMed
2. Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol
2015;44:186-98. DOI PubMed
3. Lee MS, Pant S. Personalizing medicine with germline and somatic sequencing in advanced pancreatic cancer: current treatments and
novel opportunities. Am Soc Clin Oncol Educ Book 2021;41:1-13. DOI PubMed
4. Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev
Gastroenterol Hepatol 2020;17:153-68. DOI PubMed
5. Llach J, Carballal S, Moreira L. Familial pancreatic cancer: current perspectives. Cancer Manag Res 2020;12:743-58. DOI PubMed
PMC
6. National Comprehensive Cancer Network (NCCN). Pancreatic adenocarcinoma guidelines. Available from:
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455 [Last accessed on 14 September 2022].
7. Fathi A, Christians KK, George B, et al. Neoadjuvant therapy for localized pancreatic cancer: guiding principles. J Gastrointest
Oncol 2015;6:418-29. DOI PubMed PMC
8. Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD, Del Chiaro M. Neoadjuvant treatment in pancreatic cancer. Front Oncol
2020;10:245. DOI PubMed PMC
9. Leal AD, Messersmith WA, Lieu CH. Neoadjuvant treatment of localized pancreatic adenocarcinoma. J Gastrointest Oncol
2021;12:2461-74. DOI PubMed PMC
10. Yang K, Li Y, Lian G, et al. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK
pathway in pancreatic cancer. Int J Cancer 2018;142:2323-34. DOI PubMed
11. Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M. Mutant p53 stimulates chemoresistance of pancreatic
adenocarcinoma cells to gemcitabine. Biochim Biophys Acta 2015;1853:89-100. DOI PubMed
12. Swayden M, Iovanna J, Soubeyran P. Pancreatic cancer chemo-resistance is driven by tumor phenotype rather than tumor genotype.
Heliyon 2018;4:e01055. DOI PubMed PMC
13. Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol
Hematol 2017;114:139-52. DOI PubMed
14. Ramachandran K, Miller H, Gordian E, Rocha-Lima C, Singal R. Methylation-mediated silencing of TMS1 in pancreatic cancer and
its potential contribution to chemosensitivity. Anticancer Res 2010;30:3919-25. PubMed